Placeholder Banner

BIO Comments on Upcoming ODAC Pediatric Oncology Subcommittee Meeting

April 27, 2022

On Wednesday, April 27th, BIO submitted comments regarding an upcoming meeting of ODAC’s Pediatric Oncology Subcommittee on PREA Waivers for Same-in-Class Drugs. In particular, the subcommittee will meet to discuss the development of a conceptual framework that will inform the decision making of FDA on sponsor plans and requests for waivers of early pediatric investigations of molecularly targeted cancer drugs and biologics when multiple same-in-class products are approved and/or in development, recognizing that the rarity of pediatric cancers may preclude the feasibility of investigations of multiple products. In the comments submitted, BIO stated support for the development of a conceptual framework as the absence of an effective mechanism for making decisions about the feasibility of preliminary efficacy studies may increase the likelihood that studies cannot be fully enrolled, an outcome undesirable to all stakeholders. However, BIO emphasized that the construction of a conceptual framework to assist FDA’s regulatory decision making should avoid unduly burdening one sponsor more than its competitors, utilize scientific data (e.g., mechanistic, nonclinical, clinical, etc.), and have a patient-centric approach. 

Download Full Comments Below
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee: Points for Consideration Regarding Sponsor Plans and Waiver Requests
Discover More
On October 28th, BIO submitted comments on the ICH E11A Pediatric Extrapolation Guideline as published by the Food & Drug Administration (FDA). In the comments submitted, BIO voiced appreciation for the guideline’s clear explanation for how…
On November 1st, BIO submitted comments in response to the Food & Drug Administration’s (FDA) recent Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. The meeting was primarily focused on two topics: the future of the…
On Friday, September 23rd, BIO submitted comments in response to a new draft guidance describing FDA’s perspective on its use of remote regulatory assessments (RRAs). In particular, the draft guidance responded to frequently asked questions on what…